Cwm LLC Increases Stake in Exelixis, Inc. (NASDAQ:EXEL)

Cwm LLC increased its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 32.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,176 shares of the biotechnology company’s stock after purchasing an additional 2,478 shares during the period. Cwm LLC’s holdings in Exelixis were worth $244,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Contravisory Investment Management Inc. purchased a new stake in shares of Exelixis in the 4th quarter valued at $26,000. Fifth Third Bancorp boosted its position in Exelixis by 44.2% during the 3rd quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 604 shares during the period. Signaturefd LLC boosted its position in Exelixis by 17.1% during the 3rd quarter. Signaturefd LLC now owns 4,577 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 668 shares during the period. Headlands Technologies LLC purchased a new stake in Exelixis during the 3rd quarter valued at $100,000. Finally, Quantbot Technologies LP boosted its position in Exelixis by 131.4% during the 3rd quarter. Quantbot Technologies LP now owns 5,770 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 3,277 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In other news, Director David Edward Johnson purchased 190,000 shares of the stock in a transaction on Wednesday, February 21st. The shares were acquired at an average price of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the acquisition, the director now directly owns 1,100,730 shares of the company’s stock, valued at $22,785,111. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director David Edward Johnson bought 190,000 shares of the stock in a transaction dated Wednesday, February 21st. The shares were purchased at an average price of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the acquisition, the director now owns 1,100,730 shares of the company’s stock, valued at $22,785,111. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Alan M. Garber sold 19,205 shares of the business’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the transaction, the director now directly owns 35,703 shares in the company, valued at approximately $857,229.03. The disclosure for this sale can be found here. Insiders own 2.85% of the company’s stock.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $21.90 on Friday. Exelixis, Inc. has a 1-year low of $18.52 and a 1-year high of $24.34. The company has a market capitalization of $6.38 billion, a P/E ratio of 34.22, a P/E/G ratio of 0.57 and a beta of 0.57. The firm’s 50 day simple moving average is $22.97 and its two-hundred day simple moving average is $22.22.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.16). Exelixis had a net margin of 11.10% and a return on equity of 8.85%. The firm had revenue of $425.23 million for the quarter, compared to analysts’ expectations of $461.04 million. During the same period in the prior year, the firm earned $0.12 EPS. Exelixis’s revenue for the quarter was up 4.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Exelixis, Inc. will post 1.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on EXEL shares. HC Wainwright reissued a “buy” rating and set a $28.00 price target on shares of Exelixis in a research report on Friday. JMP Securities reiterated a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a research note on Wednesday, April 10th. Stifel Nicolaus increased their price objective on shares of Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Friday, February 2nd. William Blair reissued an “outperform” rating on shares of Exelixis in a research report on Wednesday. Finally, TD Cowen increased their price objective on shares of Exelixis from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday. Six analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Exelixis has a consensus rating of “Moderate Buy” and an average price target of $26.33.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.